Intellia Therapeutics highlights its anticipated 2024 key milestones
Intellia Therapeutics today announced its strategic priorities through 2026 and key anticipated 2024 milestones that support the company’s mission to transform the lives of patients and bring forth a new era in medicine.
Intellia anticipates initiating the global pivotal Phase 3 trial of NTLA-2002 in HAE in the second half of 2024, subject to regulatory feedback. The company also expects to present updated data from Phase 1 and new data from Phase 2 portion in 2024.
NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.
John Leonard MD, Intellia President and Chief Executive Officer, said: “Looking ahead, we will continue to turn ground-breaking science into real-world medicines by capitalizing on our extensive experience and capabilities to edit disease-causing genes. We are rapidly expanding the potential to treat an even larger range of diseases, including those that originate outside of the liver, by deploying our novel delivery and editing technologies. With our comprehensive gene editing toolbox, we are well-positioned to harness the full potential of CRISPR-based medicines for patients.”
(Source: Intellia)
